Search Results
147 results found-
CSL will continue to monitor and assess relevant physical and transition climate risks and opportunities.
https://www.csl.com/sustainability/healthier-environment/climate-resilience -
Injectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure - Jun 5, 2023
https://newsroom.csl.com/2023-06-05-Injectafer-R-approved-in-the-U-S-for-the-treatment-of-iron-deficiency-in-patients-with-heart-failure -
Publication Grants support organizing, analyzing and publishing retrospective data that is already collected, compiled and available to the Investigator/Author.
https://www.csl.com/research-and-development/awards-grants-and-initiatives/publication-grants -
Published results from the preclinical studies of CSL's self-amplifying messenger RNA (sa-mRNA) influenza vaccine candidates, the next generation of mRNA vaccines, indicate a potent, cross-reactive immune response against pandemic and seasonal influenza strains, A(H5N1) and A(H1N1).
https://newsroom.csl.com/2022-11-02-Next-Generation-mRNA,-Gene-Therapy,-Plasma-Products,-Monoclonal-Antibodies,-and-Recent-Acquisitions-and-Collaborations-Highlight-CSL-R-D-Day-2022 -
CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)] 4- and 5-Gram Vials - Jan 2, 2024
https://newsroom.csl.com/2024-01-02-CSL-Behring-Demonstrates-Continued-Commitment-to-Alpha-1-Community-with-Addition-of-ZEMAIRA-R-Alpha1-Proteinase-Inhibitor-Human-4-and-5-Gram-Vials -
CSL's product portfolio focuses on innovation in new products, improved products and manufacturing expertise thereby ensuring our continued growth.
https://www.csl.com/research-and-development/product-pipeline -
Biotech leader CSL has manufacturing centers, sales offices, and locations to serve patients and public health around the globe.
https://www.csl.com/we-are-csl/worldwide-locations -
As part of its ongoing commitment to making a positive Economic, Social and Environmental (ESG) contribution to the communities it supports, CSL Behring is also entering its 5 th multiyear commitment to donate coagulation factor therapies to the WFH.
https://newsroom.csl.com/2022-04-28-CSL-Behring-Donates-500-Million-International-Units-of-Coagulation-Factor-Replacement-Therapy-to-the-World-Federation-of-Hemophilia-Humanitarian-Aid-Program-to-Help-Those-Living-with-Bleeding-Disorders -
If you have preexisting risk factors for liver cancer, regular liver health testing will continue for 5 years post-administration.
https://newsroom.csl.com/2023-10-27-CSL-and-uniQure-Win-2023-Prix-Galien-USA-Award